Logo

BMS Presents Results of Opdivo (nivolumab) in P-III (CheckMate-816) Trial as Neoadjuvant Treatment for Resectable Non-Small Cell Lung Cancer at AACR 2022

Share this

BMS Presents Results of Opdivo (nivolumab) in P-III (CheckMate-816) Trial as Neoadjuvant Treatment for Resectable Non-Small Cell Lung Cancer at AACR 2022

Shots:

  • The P-III (CheckMate-816) trial evaluates Opdivo (360mg, q3w for 3 cycles) + CT vs CT alone in 358 patients with resectable stage IB to IIIA NSCLC
  • The results showed an improvement in EFS, 37% reduction in risk of disease recurrence, progression, or death with a minimum follow-up of 21.0mos., m-EFS (31.6mos. vs 20.8mos.) while the data are still immature & the analysis did not reach statistical significance with favorable early OS results. The results were published in NEJM
  • Patients were alive (83% vs 71%) @2yrs., OS will continue to be followed for upcoming analyses & the safety profile was consistent with previous reports with no new safety signals at the time of the EFS analysis

Ref: BMS | Image: BMS

Click here to­ read the full press release 

Senior Editor

Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Related News/Articles

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions